Capitalizing R&D: Learn What GAAP Fails To Teach You

Last we discussed Accounts Payable and the role they play in cash flow efficiency. We learned that one company’s A/R is another company’s A/P. This week we’re analyzing one of the more complex accounting problems: capitalizing research & development (R&D) costs.

We’ll learn the difference between capitalizing vs. expensing, why it matters and how it changes margins, profits and returns.

Why We Should Capitalize R&D Costs

US GAAP accounting requires companies to treat R&D as expenses on the income statement (P&L). That biotech company spending $1M developing a new drug? Under GAAP that’s a $1M expense, not an asset.

This distorts profits, margins and ROA calculations for many tech/R&D heavy firms. That’s not ideal. Think about it. Companies that leverage R&D to generate revenue and cash have periods of massive R&D investment.

If you don’t adjust for R&D, the income statement looks like a bouncy ball on cocaine.

Investments in R&D support the long-term cash-flow generation of a company. They’re operating assets. As such, we should capitalize them on the balance sheet.

Capitalizing R&D is also a more conservative estimation of a company’s returns and profitability for two reasons:

    1. Capitalizing increases a company’s total assets (which could reduce ROA/ROE)
    2. Capitalizing keeps an amortization expense on the income statement

Let’s learn how to do that.

Capitalizing R&D Investments (Step-By-Step): Boeing, Inc. (BA)

We’re using Boeing (BA) as our example. Remember, we’re keeping things simple with this example. You can get more complex (see here), but that’s not our goal.

Step 1: Find Amortization Duration 

The first step in capitalizing R&D is to determine the useful life of a company’s R&D assets. The longer the usefulness, the longer the amortization period (i.e., how many years we expense). High-tech companies in ever-changing industries have low amortization periods.

BA makes airplanes that have long lifespans. We’ll use ten years.

Step 2: Calculate Value of Amortized R&D Asset

We calculate the amortized value of the R&D asset by using the straight-line amortization method. This means we amortize 1/10th of the total sum of the last ten years’ R&D expense. If we chose 7 years, we’d amortize 1/7th of the total sum of the last seven years’ R&D expense.

Then we calculate the annual amortization expense by dividing that year’s R&D by 1/10th (0.1).

Here’s what that looks like:

Step 3: Recalculate Book Value of Equity

We need to add our capitalized R&D value to tangible book value to get a better picture of the company. This is simple. Take Tangible Book Value and add R&D value.

Here’s what that looks like in 2018:

$339M (BV) + $3.27B (R&D value) = $4.059B

Step 4: Recalculate EBIT

Next we adjust EBIT to reflect our capitalized R&D investments. To do this, we take our current year EBIT, add current year R&D expense and subtract total amortization of R&D.

Here’s what that looks for BA in 2018:

$11.6B (EBIT) + $3.27B (R&D) – $3.71B (Amortization) = $11.16B Adjusted EBIT

Why does EBIT drop after adjusting for R&D investment? BA’s decreasing R&D investment (see above).

To Be Continued …

I know, capitalizing R&D is confusing. But it’s important if we want to understand the true economics of an investment-heavy business.

We’ll review this concept in more detail next week, don’t worry.

If you have any questions feel free to reach out.

All content on our website, emails, social media posts, comments on other websites or other material generated by Macro Ops is intended for general information purposes only. None of our content should be considered to be an invitation to buy or sell securities. No content from Macro Ops should be considered individual investment advice. Macro Ops cannot guarantee accuracy of information on the site. Contributors to Macro Ops may have trading or investing positions in the securities mentioned. You should assume that we are likely to take trading positions in the stocks, options, futures or other securities we write about. Macro Ops does not have an obligation to inform readers of a change of opinion on securities mentioned or on a change in our trading positions on securities mentioned. Macro Ops assumes no liability for losses incurred from readers trading securities that are mentioned in any of our content. None of the media brands in the “Featured In” section have directly endorsed our products or services. For full disclaimer, please visit: https://macro-ops.com/terms-of-service/ Copyright © 2020 Foundation Alpha LLC. All rights reserved. - powered by Enfold WordPress Theme